Skip to main content

New Products

  • FDA approves Lupin's generic version of Ambien CR

    BALTIMORE — The Food and Drug Administration has approved a generic drug for insomnia made by Lupin, the drug maker said.

    The FDA approved zolpidem tartrate extended-release tablets in the 6.25-mg and 12.5-mg strengths, a generic version of Sanofi's Ambien CR.

    The branded version of the drug had sales of $366 million during the 12-month period ended in March, according to IMS Health.

     

  • Teva wins approval for liquid version of cancer drug

    JERUSALEM — The Food and Drug Administration has approved a new formulation of a cancer drug made by Teva Pharmaceutical Industries, Teva said Tuesday.

    The Israeli drug maker announced the approval of a liquid formulation of Treanda (bendamustine hydrochloride), which it said would eliminate the need for reconstitution.

    The drug is used to treat indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab), which is made by Genentech and Biogen Idec, and in patients with chronic lymphocytic leukemia.

  • Market saturation to cause electronic health record market to decline

    TORONTO — Market saturation will drive down the market for electronic medical records in the United States despite a spike last year resulting from government incentive funding, according to a new study.

    The Millennium Research Group predicts that due to Medicare penalties for hospitals and physicians that fail to demonstrate meaningful use of electronic medical records by 2015, most adoption will occur by then. But market saturation means that purchases of new systems will likely decline.

  • FDA approves new Dr. Reddy's injectable drug

    HYDERABAD, India — The Food and Drug Administration has approved an injected drug for the bone marrow disorder myelodysplastic syndrome made by Dr. Reddy's Labs, the company said Tuesday.

    Dr. Reddy's announced the approval of azacitidine injection in the 100-mg-per-vial strength. The drug is a generic version of Celgene's Vidaza, and Dr. Reddy's plans to launch the product in the near future.

    Vidaza had sales of about $378.5 million during the 12-month period ended in July, according to IMS Health.

     

  • Hefty introduces new odor-control bags with Arm & Hammer

    LAKE FOREST, Ill. — Hefty announced on Tuesday a new trash bag with advanced odor-control, the company stated.

    Hefty Ultimate with Arm & Hammer provides a trio of advanced technology to give the consumer everything needed in one bag. The Arm & Hammer patented odor-neutralizing technology helps eliminate kitchen odors. Hefty Ultimate bags come in scent-free, lavender and clean burst scents.

  • Speck introduces new iPhone 5s case with slim-fitting design

    MOUNTAIN VIEW, Calif. — Speck, a designer of slim-fitting protective cases and covers for smartphones, tablets and laptops, on Tuesday announced a new iPhone case for the iPhone 5 and 5s.

  • Stiefel launches new acne drug

    NEW YORK — Stiefel has launched a new drug for treating acne, the company said Tuesday.

    Stiefel, which is a subsidiary of British drug maker GlaxoSmithKline, announced the launch of Fabior (tazarotene) foam, which it called the only retinoid in a topical foam formulation for acne vulgaris in patients aged 12 and older.

    The drug originally received Food and Drug Administration approval in May 2012.

  • TV personality Bill Rancic joins Mission Pharmacal for distribution celebration

    CHICAGO — Entrepreneur and TV personality Bill Rancic joined the Dr. Smith's Diaper Rash Ointment team to celebrate the launch of the brand in Walgreens stores across the country, Mission Pharmacal announced Monday. Mission Pharmacal hosted the party to introduce the popular diaper rash ointment to Chicago moms and dads.

X
This ad will auto-close in 10 seconds